Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis b virus infection
Ended Project Grant Awarded Last action
- Award ID
- R44AI155308
- Recipient
-
Venatorx Pharmaceuticals Inc. UEI MBBKNBU5DCC6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $8,000,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $5,999,999.98 Federal
- $2,000,000.00 Non-federal
- Place of performance
- Pennsylvania, USA
Award details come from USAspending.gov.
Description
- Abstract
- Despite the availability of a safe and effective vaccine, there remains over 257 million people chronically infected with hepatitis b virus (HBV) world-wide. Individuals with chronic HBV infections are at risk for complications due to liver disease and liver cancer. Chronic HBV is currently managed with nucleos(t)IDE reverse transcriptase inhibitors (nrti) which partly suppress HBV DNA replication, normalize alanine aminotransferase levels (ALT) and slow disease progression. Front-line therapies, however, are not curative and patients with chronic HBV exhibit poor off-treatment responses requiring life-long therapy. New antivirals and immunomodulatory approaches are, therefore, needed to further suppress viral replication and provide the conditions that are required for immune control known as a "functional cure". One of the most promising classes of compounds under investigation are the core protein allosteric modulators (cpam) that block HBV replication at multiple stages of the viral life-cycle. Here, we report on a best-in-class cpam that exhibits potent pan-genotypic antiviral activity. In this project, we propose to advance our lead cpam into definitive indenabling studies to ready the compound for phase 1 clinical trials in healthy volunteers and chronic HBV patients. Combination regimens that include a cpam, antivirals possessing distinct mechanisms of action and/or novel immunomodulatory agents will be evaluated in a mouse model of HBV infection in preparation for phase 2 development in chronic HBV patienst.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$0 | $0 | |
| Amendment | $1,000,000 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,000,000 | $0 | |
| Amendment | $1,000,000 | $1,000,000 | |
| Amendment | $1,000,000 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,000,000 | $0 | |
| Original award | $1,000,000 | $1,000,000 |
Show all 12
Quick answers
Who received award R44AI155308?
R44AI155308 was awarded to Venatorx Pharmaceuticals Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 24, 2021.
How much is award R44AI155308 worth?
$8,000,000 has been obligated on R44AI155308: $6,000,000 in federal funding and $2,000,000 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award